%0 Journal Article
%A Emmanouilidou, E
%A Papagiannakis, N
%A Kouloulia, S
%A Galaziou, A
%A Antonellou, R
%A Papadimitriou, D
%A Athanasiadou, A
%A Bozi, M
%A Koros, C
%A Maniati, M
%A Vekrellis, K
%A Ioannou, PC
%A Stefanis, L
%D 2020
%F discovery:10099182
%J Parkinsonism & Related Disorders
%K A53T, Alpha-synuclein, Parkinson disease, Plasma, Serum
%P 35-40
%T Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease
%U https://discovery.ucl.ac.uk/id/eprint/10099182/
%V 73
%X BACKGROUND: Variations of α-synuclein levels have been reported in serum and plasma in Parkinson's Disease (PD) Patients. METHODS: Serum and plasma were obtained from PD patients without known mutations (GU-PD, n = 124)), carriers of the A53T/G209A point mutation in the α-synuclein gene (SNCA) (n = 29), and respective age-/sex-matched controls. Levels of total α-synuclein were assessed using an in-house ELISA assay. RESULTS: A statistically significant increase of α-synuclein levels was found in serum, but not plasma, from GU-PD patients compared to healthy controls. A statistically significant decrease of α-synuclein levels was found in serum and plasma from symptomatic A53T mutation carriers compared to healthy controls. Plasma α-synuclein levels were modestly negatively correlated with UPDRS part III score and disease duration in A53T-PD patients. CONCLUSION: Increased α-synuclein levels in serum of GU-PD patients suggest a systemic deregulation of α-synuclein homeostasis in PD. The opposite results in A53T-PD highlight the complexity of α-synuclein homeostatic regulation in PD, and suggest the possibility of reduced expression of the mutant allele.
%Z This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.